CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

patiromer

Last Updated: May 13, 2021
Result type: Reports
Project Number: SR0665-000
Product Line: Reimbursement Review

Generic Name: patiromer

Brand Name: Veltassa

Manufacturer: Otsuka Canada Pharmaceuticals Inc.

Therapeutic Area: Hyperkalemia, adults (chronic kidney disease)

Indications: For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).

Manufacturer Requested Reimbursement Criteria1: For the treatment of hyperkalemia in adults with CKD 3-4 on RAASi therapy.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2

Call for patient/clinician input open October 02, 2020
Call for patient/clinician input closed November 23, 2020
Clarification:

- Patient input submission received from the The Kidney Foundation of Canada

Submission received October 30, 2020
Submission accepted November 13, 2020
Review initiated November 16, 2020
Draft CADTH review report(s) provided to sponsor for comment February 25, 2021
Deadline for sponsors comments March 08, 2021
CADTH responses on draft review report(s) provided to sponsor April 09, 2021
Expert committee meeting (initial) April 21, 2021
Draft recommendation issued to sponsor May 03, 2021
Draft recommendation posted for stakeholder feedback May 13, 2021
End of feedback period May 28, 2021